Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma ( CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial
Nivolumab plus Chemotherapie oder Ipilimumab versus Chemotherapie bei Patient:innen mit fortgeschrittenem ösophagealem Plattenepithelkarzinom (CheckMate 648): 29-Monats-Follow-up einer randomisierten, offenen Phase-III-Studie
Cancer Medicine · 2024-05 · 13 (9)
DOI: 10.1002/cam4.7235 ↗Auf einen Blick
Bei fortgeschrittenem ESCC blieb Nivolumab plus Chemotherapie oder Ipilimumab der Chemotherapie in Bezug auf das Gesamtüberleben überlegen. Für die Chemotherapie-Kombination zeigte sich auch ein PFS-Vorteil bei PD-L1 ≥1 %.
Fragestellung
Verbessern Nivolumab plus Chemotherapie oder Nivolumab plus Ipilimumab das Überleben gegenüber Chemotherapie bei zuvor unbehandeltem, fortgeschrittenem ESCC?
Methode
Offene Phase-III-Studie; 1:1:1-Randomisierung zu Nivolumab plus Chemotherapie, Nivolumab plus Ipilimumab oder Chemotherapie; 29 Monate Mindest-Follow-up.
Ergebnisse
970 Patient:innen randomisiert. OS: HR 0,59 (95 %-KI 0,46–0,76) bzw. 0,78 (95 %-KI 0,65–0,93) für Nivolumab plus Chemotherapie vs. Chemotherapie; HR 0,62 (95 %-KI 0,48–0,80) bzw. 0,77 (95 %-KI 0,65–0,92) für Nivolumab plus Ipilimumab. PFS bei PD-L1 ≥1 %: HR 0,67 (95 %-KI 0,51–0,89); HR 1,04 (95 %-KI 0,79–1,36).
Schlussfolgerung der Autor:innen
Nivolumab plus Chemotherapie und Nivolumab plus Ipilimumab zeigten weiterhin einen klinisch relevanten OS-Vorteil gegenüber Chemotherapie ohne neue Sicherheitssignale.
Kernaussagen
- OS-Vorteil unter beiden Nivolumab-Regimen gegenüber Chemotherapie
- PFS-Vorteil nur für Nivolumab plus Chemotherapie bei PD-L1 ≥1 %
- Grad-3–4 therapiebedingte UAW bei 49 %, 32 % und 36 %
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Cancer Medicine, online erschienen am 08.05.2024. Verfasst von Ken Kato und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Ipilimumab, Nivolumab, Esophageal Squamous Cell Carcinoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb in collaboration with Ono Pharmaceutical Co..
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcinoma (ESCC) in the CheckMate 648 trial, leading to approvals of both nivolumab‐containing regimens in many countries. We report longer‐term follow‐up data.
Methods
This open‐label, phase III trial (NCT03143153) enrolled adults with previously untreated, unresectable, advanced, recurrent, or metastatic ESCC. Patients were randomized 1:1:1 to nivolumab plus chemotherapy, nivolumab plus ipilimumab, or chemotherapy. Primary endpoints were OS and progression‐free survival (PFS) by blinded independent central review. Hierarchical testing was performed first in patients with tumor cell programmed death ligand 1 (PD‐L1) expression of ≥1% and then in the overall population.
Results
A total of 970 patients were randomly assigned. After 29 months of minimum follow‐up, nivolumab plus chemotherapy continued to demonstrate improvement in OS versus chemotherapy (hazard ratio [HR] = 0.59 [95% CI: 0.46–0.76]) in patients with tumor cell PD‐L1 expression of ≥1% and in the overall population (HR = 0.78 [95% CI: 0.65–0.93]) and with nivolumab plus ipilimumab versus chemotherapy (HR = 0.62 [95% CI: 0.48–0.80]) in patients with tumor cell PD‐L1 expression of ≥1% and in the overall population (HR = 0.77 [95% CI: 0.65–0.92]). In patients with tumor cell PD‐L1 expression of ≥1%, nivolumab plus chemotherapy demonstrated PFS benefit versus chemotherapy (HR = 0.67 [95% CI: 0.51–0.89]); PFS benefit was not observed with nivolumab plus ipilimumab versus chemotherapy (HR = 1.04 [95% CI: 0.79–1.36]). Among all treated patients ( n = 936), Grade 3–4 treatment‐related adverse events were reported in 151 (49%, nivolumab plus chemotherapy), 105 (32%, nivolumab plus ipilimumab), and 110 (36%, chemotherapy) patients.
Conclusions
Nivolumab plus chemotherapy and nivolumab plus ipilimumab continued to demonstrate clinically meaningful OS benefit versus chemotherapy with no new safety signals identified with longer follow‐up, further supporting use as first‐line standard treatment options for patients with advanced ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Osaka University Graduate School of Medicine, Osaka, Japan.
- Royal Marsden Hospital, London & Surrey, UK.
- Department of Gastrointestinal Oncology, The Fifth Medical Center of the PLA General Hospital, Beijing, China.
- Klinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warszawa, Poland.
- Akita University Hospital, Akita, Japan.
ORCID-Profile: Ken Kato, Jaffer Ajani
Förderung
- Bristol Myers Squibb in collaboration with Ono Pharmaceutical Co.
Zitieren
APA
Kato, K., Doki, Y., Chau, I., Xu, J., Wyrwicz, L., Motoyama, S., Ogata, T., Kawakami, H., Hsu, C. H., Adenis, A., El Hajbi, F., Di Bartolomeo, M., Braghiroli, M. I., Holtved, E., Makino, T., Blum Murphy, M., Amaya-Chanaga, C., Patel, A., Hu, N., …, & Ajani, J. (2024). Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma ( CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial. Cancer Medicine, 13(9). https://doi.org/10.1002/cam4.7235
Vancouver
Kato K, Doki Y, Chau I, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma ( CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial. Cancer Medicine. 2024;13(9). doi:10.1002/cam4.7235
BibTeX
@article{Kato2024,
author = {Kato, Ken and Doki, Yuichiro and Chau, Ian and Xu, Jianming and Wyrwicz, Lucjan and Motoyama, Satoru and Ogata, Takashi and Kawakami, Hisato and Hsu, Chih-Hung and Adenis, Antoine and El Hajbi, Farid and Di Bartolomeo, Maria and Braghiroli, Maria Ignez and Holtved, Eva and Makino, Tomoki and Blum Murphy, Mariela and Amaya-Chanaga, Carlos and Patel, Apurva and Hu, Nan and Matsumura, Yasuhiro and Kitagawa, Yuko and Ajani, Jaffer},
title = {Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma ( CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {9},
doi = {10.1002/cam4.7235}
}
EUVIMED